CLPT earnings analysis
What we found in CLPT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ClearPoint Neuro delivered $10.880 million of Q2 revenue, up 18% year over year but down roughly 10% from Q1 2026, with growth concentrated in neurosurgery navigation and therapy. Gross margin improved 2 points to 62%, but IRRAS-related commercial expansion and other operating costs drove the net loss to $11.337 million and EPS to negative $0.38. Liquidity was $29.4 million of cash, while first-half operating cash burn rose to $14.982 million; management expects burn to improve after IRRAS integration.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 18% year over year
- Q2 revenue increased 18% year over year to $10.880 million from $9.215 million. First-half revenue increased 30% to $23.008 million from $17.700 million.
- Procedure-oriented franchises accelerated
- Neurosurgery navigation and therapy revenue rose 62% to $5.552 million, driven by IRRAflow sales and ClearPoint Navigation Software 3.0, while capital equipment and software rose 24% to $1.297 million.
- Gross margin expanded 2 points
- Gross margin improved to 62% from 60% a year earlier, producing gross profit of $6.710 million versus $5.556 million; management attributed the expansion primarily to lower excess and obsolete inventory.
- Cash supports stated 12-month runway
- Liquidity included $29.4 million of cash and cash equivalents at June 30, 2026. The company also had received approximately $48.1 million of net proceeds from two notes under a facility allowing up to $105.0 million in aggregate principal.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and operating margin deteriorated sharply
- The Q2 net loss nearly doubled to $11.337 million from $5.837 million, and diluted EPS declined to negative $0.38 from negative $0.21. Operating loss was approximately $10.244 million, equal to a negative 94.2% operating margin on $10.880 million of revenue.
- Sequential slowdown and biologics volatility
- Revenue declined approximately 10% sequentially from $12 million in Q1 2026 to $10.880 million in Q2, while gross margin fell from 64.0% to 62.0%. Biologics and drug delivery revenue fell 15% year over year to $4.031 million because a prior-year customer product order did not recur.
- Post-acquisition cost growth outpaced revenue
- Operating costs grew materially faster than sales: sales and marketing rose 68% to $6.768 million, general and administrative expense rose 64% to $5.554 million, and R&D rose 21% to $4.632 million, versus 18% revenue growth.
- Operating cash burn increased
- Six-month operating cash use increased to $14.982 million from $8.724 million. Adding $0.859 million of equipment acquisitions implies approximately $15.841 million of six-month cash use before financing, despite management expecting operating cash use to decrease in the remainder of 2026.
- New CAL facility execution risk
- The sole material risk-factor update concerns execution of the preclinical CRO facility, CAL. The company has $29.4 million of cash at June 30, 2026, but warns that CAL requires upfront fixed costs and may not generate enough demand or revenue to justify the investment.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.38
- Gross margin
- 62.0%
- Operating margin
- -94.2%
- Segment
- Biologics and drug delivery: $4.031 million, down 15% year over year from $4.739 million.
- Segment
- Neurosurgery navigation and therapy: $5.552 million, up 62% year over year from $3.432 million.
- Segment
- Capital equipment and software: $1.297 million, up 24% year over year from $1.044 million.
What they said about what is next.
The 10-Q contains no quantitative revenue or EPS outlook. Management expects revenue to grow over coming years from the IRRAS acquisition and expects operating cash use to decrease during the remainder of 2026 as IRRAS integration is completed; it also states that $29.4 million of cash and cash equivalents is sufficient for at least the next 12 months.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- ClearPoint Neuro reported a strong Q1 2026 with revenue of $12.1 million, which was above estimates of $12.03 million, marking a 43% increase year-over-year. However, the company experienced a diluted EPS loss of $0.32,…
- 10-K · March 17, 2026
- ClearPoint reported record 2025 revenue of $36.97 million (up 18% vs. 2024) driven by product revenue of $23.86 million (+28%) and a 44% increase in neurosurgery navigation & therapy revenue to $14.83 million. The…
- 10-Q · May 13, 2025
- ClearPoint reported Q1 2025 revenue of $8,485,000, up $846,000 or 11.1% year-over-year, driven by product revenue growth. Gross profit rose to $5,132,000 (60.5% margin) but operating loss widened to $6,163,000 (−72.6%…
- 10-K · February 26, 2025
- ClearPoint reported 2024 revenue of $31.39 million, up 31% year-over-year, driven by a 76% increase in product revenue to $18.626 million and growth in disposables for biologics and neurosurgery. The company improved…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLPT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever